Performance evaluation of novel fluorescent-based lateral flow immunoassay (LFIA) for rapid detection and quantification of total anti-SARS-CoV-2 S-RBD binding antibodies in infected individuals.

ABSTRACT:

Background

A vast majority of the commercially available lateral flow immunoassay (LFIA) is used to detect SARS-CoV-2 antibodies qualitatively. Recently, a novel fluorescence-based lateral flow immunoassay (LFIA) test was developed for quantitative measurement of the total binding antibody units (BAUs) (BAU/mL) against SARS-CoV-2 spike protein receptor-binding domain (S-RBD).

Aim

This study aimed to evaluate the performance of the fluorescence LFIA Finecare^TM 2019-nCoV S-RBD test along with its reader (Model No.: FS-113).

Methods

Plasma from 150 reverse trancriptase-PCR (RT-PCR)-confirmed positive individuals and 100 prepandemic samples were tested by Fincare^TM to access sensitivity and specificity. For qualitative and quantitative validation of

SUBMITTER: Shurrab FM 

PROVIDER: S-EPMC8882034 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature